Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy

NCT06699108 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Bietti Crystalline Dystrophy
Inherited Retinal Diseases

Interventions

DRUG: VGR-R01

Sponsor

Shanghai Vitalgen BioPharma Co., Ltd.